Open AccessA Liquid Biopsy to Assess Brain Tumor Recurrence: Presence of Circulating Mo-MDSC and CD14+ VNN2+ Myeloid Cells as Biomarkers That Distinguish Brain Metastasis From Radiation Necrosis Following Stereotactic Radiosurgery
Author(s) -
David Soler,
Amber Kerstetter-Fogle,
Theresa Elder,
Alankrita Raghavan,
Jill S. BarnholtzSloan,
Kevin D. Cooper,
Thomas S. McCormick,
Andrew E. Sloan
Publication year - 2020
Publication title -
neurosurgery/neurosurgery online
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.455
H-Index - 198
eISSN - 1081-1281
pISSN - 0148-396X
DOI - 10.1093/neuros/nyaa334
Subject(s) - medicine , stereotactic biopsy , brain metastasis , radiosurgery , biopsy , cd14 , pathology , myeloid , brain biopsy , malignancy , metastasis , cancer , flow cytometry , radiation therapy , immunology
Brain metastases (BM) are the most common type of brain tumor malignancy in the US. They are also the most common indication for stereotactic radiosurgery (SRS). However, the incidence of both local recurrence and radiation necrosis (RN) is increasing as treatments improve. MRI imagery often fails to differentiate BM from RN; thus, patients must often undergo surgical biopsy or resection to obtain a definitive diagnosis.